Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study

Author's Avatar
Jul 06, 2022

Three Arm, Randomized, Double-Blind, Vehicle Controlled Study Will Test Two Doses of QRX003 Versus Vehicle